Top Page
Botanix Pharmaceuticals Limited
(Sydney:BOT)
Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)
Botanix Pharmaceuticals Limited Business Overview & Revenue Model
Botanix Pharmaceuticals Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.07M | 601.82K | 914.97K | 2.75M | 6.89M | 7.57M | Gross Profit |
| -1.81M | -6.55M | -3.05M | 2.61M | 6.79M | 7.47M | EBIT |
| -39.82M | -15.46M | -12.80M | -15.94M | -10.27M | -24.26M | EBITDA |
| -39.25M | -13.92M | -9.11M | -15.74M | -10.06M | -24.14M | Net Income Common Stockholders |
| -39.29M | -13.87M | -9.15M | -13.17M | -3.33M | -16.73M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 18.31M | 79.31M | 10.25M | 7.29M | 21.55M | 24.65M | Total Assets |
| 47.68M | 112.46M | 24.84M | 14.04M | 21.95M | 25.31M | Total Debt |
| 0.00 | 0.00 | 0.00 | 122.41K | 259.32K | 420.62K | Net Debt |
| -18.31M | -79.31M | -10.25M | -7.16M | -21.30M | -24.22M | Total Liabilities |
| 2.29M | 3.73M | 1.88M | 5.89M | 1.15M | 1.67M | Stockholders Equity |
| 45.39M | 108.73M | 22.95M | 8.15M | 20.80M | 23.64M |
| Cash Flow | Free Cash Flow | ||||
| -35.10M | -26.13M | -19.13M | -14.11M | -2.98M | -17.45M | Operating Cash Flow |
| -34.93M | -8.13M | -12.07M | -11.18M | -2.97M | -17.36M | Investing Cash Flow |
| -4.08M | -18.00M | -7.05M | -2.92M | -8.28K | -151.19K | Financing Cash Flow |
| 68.74M | 95.10M | 22.03M | -152.41K | -125.50K | 37.31M |
Botanix Pharmaceuticals Limited Technical Analysis
Botanix Pharmaceuticals Limited Peers Comparison
Botanix Pharmaceuticals Limited Corporate Events
UniSuper Limited, as a trustee for UniSuper and UniSuper Management Pty Limited, has become a substantial holder in Botanix Pharmaceuticals Limited as of April 24, 2025, with a 5.14% voting power through ownership of 100,455,466 ordinary shares. This acquisition indicates a significant investment in Botanix Pharmaceuticals, potentially impacting the company’s market positioning and signaling confidence in its strategic direction, which could influence other stakeholders and investors.
Botanix Pharmaceuticals Limited has successfully raised A$40 million through the issuance of 121,212,122 new fully paid ordinary shares at A$0.33 each. This capital raise, announced earlier in April, allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act. This move is expected to strengthen Botanix’s financial position, enabling further development and commercialization of its dermatological products.
Botanix Pharmaceuticals Limited has announced the application for the quotation of 121,212,122 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations. The issuance of these securities could strengthen Botanix’s position in the pharmaceutical market, offering potential benefits to stakeholders by increasing the company’s financial flexibility.
Botanix Pharmaceuticals has successfully completed the commercial launch of its Sofdra™ topical gel, reporting strong initial sales figures with over 500 new patient arrivals per week and 1,500 prescribers engaged. The company has also secured a $40 million capital raise to accelerate the product’s commercialization, aiming to expand its sales force and digital marketing efforts, which is expected to enhance its market position and drive further revenue growth.
Botanix Pharmaceuticals Limited has announced a webinar to update stakeholders on the recent placement and the commercial launch of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis. The webinar, hosted by key company executives, aims to provide insights into the company’s strategic initiatives and market positioning, potentially impacting its operations and stakeholder interests.
Botanix Pharmaceuticals Limited has announced a proposed issue of 121,212,122 ordinary fully paid securities, with the issue date set for April 24, 2025. This move is part of a strategic effort to raise capital, potentially enhancing the company’s operational capabilities and market positioning, which could have significant implications for its stakeholders.
Botanix Pharmaceuticals Limited has secured $40 million through an institutional placement to accelerate the rollout of its dermatological product, Sofdra™, in the United States. The funds will be used to expand the sales force, enhance digital platforms, and support marketing activities, following a successful initial sales period that saw significant patient and prescriber engagement.
Botanix Pharmaceuticals Limited has requested a trading halt on its securities pending an announcement about a capital raising. This move indicates potential strategic financial activities that could impact the company’s operations and market positioning, with the trading halt expected to last until the announcement is made or normal trading resumes on April 16, 2025.
Botanix Pharmaceuticals Ltd has announced the issuance of 5,000,000 performance rights and unlisted options exercisable at $0.41 each, expiring on April 1, 2030. This move is part of an employee incentive scheme, which could enhance employee motivation and align their interests with the company’s growth objectives.
Botanix Pharmaceuticals Limited announced the cessation of certain securities, specifically 2,000,000 options and 2,000,000 performance rights, due to the conditions for these securities not being met or becoming incapable of being satisfied. This cessation may impact the company’s capital structure and reflects a strategic decision in managing its financial resources, potentially influencing stakeholder perceptions and future investment strategies.
Botanix Pharmaceuticals Limited has released a presentation containing general information about its business operations and industry data. The presentation emphasizes that the information provided is not exhaustive and should not be solely relied upon for investment decisions. It includes forward-looking statements about the company’s future plans and market conditions, highlighting the inherent risks and uncertainties involved.
Botanix Pharmaceuticals Limited has issued 3,990,099 new fully paid ordinary shares, which can now be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001. This move aligns with the company’s compliance with relevant provisions of the Corporations Act, potentially enhancing its market liquidity and investor engagement.
Botanix Pharmaceuticals Limited announced a change in the director’s interest, with Dr. Stewart Washer exercising options to acquire 3,990,099 ordinary fully paid shares, while disposing of 5,000,000 unlisted options. This transaction was executed under the company’s Employee Awards Plan, reflecting a strategic move to align management interests with shareholder value, potentially impacting the company’s market perception and stakeholder confidence.
Botanix Pharmaceuticals Ltd has announced the quotation of 3,990,099 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of February 27, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially increase its market presence, which could have implications for its stakeholders and industry positioning.
Botanix Pharmaceuticals Limited reported a significant increase in its net loss for the half-year ended December 31, 2024, with losses rising by 464.98% compared to the previous year. Despite a slight decrease in revenue, the company did not declare any dividends, indicating a challenging financial period that may impact its operational strategies and stakeholder confidence.